Beijing No.1 Biotechnology Group

Beijing No.1 Biotechnology Group is a Chinese biopharmaceutical company specializing in the development and commercialization of biochemical medicines for respiratory, immunological, and hematological disorders. The group's core operations are conducted through its subsidiary, Beijing No.1 Biochemical Pharmaceutical, which has a legacy dating back to 1958 and is a leading manufacturer of spleen amino peptides and thrombin. In 2019, the company established TianLi Biotech, a joint venture with the University of Melbourne, to advance a pipeline of novel casein kinase 1 (CK1) inhibitors. Their lead clinical candidate, TLB001, is an inhaled small molecule currently in Phase 1 trials for the treatment of idiopathic pulmonary fibrosis. The company integrates R&D, GMP-certified manufacturing, and a robust commercial network to serve the Chinese and international markets.